Patents Assigned to Fovea Pharmaceuticals
-
Patent number: 9308125Abstract: The present technology relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and a guide operable to guide a needle into the interior of an eye, characterized in that it comprises means for displacing a superficial layer (1) of the eye over an underlying layer (2) of the eye as the plate is brought into contact with the eye before the needle is guided into the interior of the eye.Type: GrantFiled: January 9, 2008Date of Patent: April 12, 2016Assignees: FOVEA PHARMACEUTICALS, FONDATION OPHTALMOLOGIQUEADOLPHE DE ROTHSCHILDInventors: Michel Paques, Pierre Roy
-
Patent number: 9249085Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.Type: GrantFiled: September 7, 2012Date of Patent: February 2, 2016Assignee: FOVEA PHARMACEUTICALSInventors: John Feutrill, Caroline Leriche, David Middlemiss
-
Publication number: 20140350019Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.Type: ApplicationFiled: September 7, 2012Publication date: November 27, 2014Applicant: FOVEA PHARMACEUTICALSInventors: John Feutrill, Caroline Leriche, David Middlemiss
-
Patent number: 8808242Abstract: The invention relates to an apparatus for injection into an eye comprising of a means for displacing a conjunctival layer of the eye over an underlying scleral layer of the eye so as to form a fold in the conjunctival layer, and means for guiding a needle through the conjunctival layer once the fold has been formed.Type: GrantFiled: November 2, 2011Date of Patent: August 19, 2014Assignee: Fovea PharmaceuticalsInventors: Michel Paques, Pierre Roy
-
Publication number: 20130315903Abstract: The invention is directed to the therapeutic use of arylsulfonamide derivatives.Type: ApplicationFiled: December 9, 2011Publication date: November 28, 2013Applicant: FOVEA PHARMACEUTICALSInventors: Pierre Belichard, Didier Pruneau
-
Publication number: 20130253027Abstract: The invention is directed to the therapeutic use of arylsulfonamide derivatives.Type: ApplicationFiled: December 9, 2011Publication date: September 26, 2013Applicant: FOVEA PHARMACEUTICALSInventors: Jean-Philippe Combal, Elisabeth Latour
-
Publication number: 20130211335Abstract: The invention relates to an apparatus for injection into an eye comprising of a means for displacing a conjunctival layer of the eye over an underlying scleral layer of the eye so as to form a fold in the conjunctival layer, and means for guiding a needle through the conjunctival layer once the fold has been formed.Type: ApplicationFiled: November 2, 2011Publication date: August 15, 2013Applicant: FOVEA PharmaceuticalsInventors: Michel Paques, Pierre Roy
-
Patent number: 8460242Abstract: The application relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and guiding means for guiding a needle into the interior of an eye, characterized in that the plate comprises a cut-out having an edge adapted to be positioned along the limbus delimiting the cornea and the sclera of the eye, so as to adjust the position of the guiding means with respect to the limbus.Type: GrantFiled: January 9, 2008Date of Patent: June 11, 2013Assignees: Fovea Pharmaceuticals, Foundation Ophtalmologiqueadolphe de RothschildInventors: Michel Paques, Pierre Roy
-
Publication number: 20130123271Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder.Type: ApplicationFiled: June 22, 2011Publication date: May 16, 2013Applicant: FOVEA PHARMACEUTICALSInventors: David Middlemiss, Caroline Leriche
-
Patent number: 8389530Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.Type: GrantFiled: December 18, 2009Date of Patent: March 5, 2013Assignee: Fovea PharmaceuticalsInventors: Caroline Leriche, Eric Auclair, Jacques Le Roux, David N. Middlemiss
-
Publication number: 20100030150Abstract: The application relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and guiding means for guiding a needle into the interior of an eye, characterized in that the plate comprises a cut-out having an edge adapted to be positioned along the limbus delimiting the cornea and the sclera of the eye, so as to adjust the position of the guiding means with respect to the limbus.Type: ApplicationFiled: January 9, 2008Publication date: February 4, 2010Applicants: FOVEA PHARMACEUTICALS, FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILDInventors: Michel Paques, Pierre Roy
-
Publication number: 20100010452Abstract: The present technology relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and a guide operable to guide a needle into the interior of an eye, characterized in that it comprises means for displacing a superficial layer (1) of the eye over an underlying layer (2) of the eye as the plate is brought into contact with the eye before the needle is guided into the interior of the eye.Type: ApplicationFiled: January 9, 2008Publication date: January 14, 2010Applicants: FOVEA PHARMACEUTICALS, FOUDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILDInventors: Michel Paques, Pierre Roy
-
Publication number: 20090285826Abstract: Pharmaceutical compositions for inhibiting, preventing or treating unwanted angiogenesis/neovascularization, including that of ocular tissues, contain agents that inhibit VEGF in combination with a second therapy, e.g., that elicited by serine proteases/thrombolytic compounds.Type: ApplicationFiled: May 4, 2007Publication date: November 19, 2009Applicants: FOVEA PHARMACEUTICALS SA, FONDATION OPHTHALMOLOGIQUE ADOLPHE DE ROTHSCHILDInventors: Sebastien Bonnel, José Sahel
-
Publication number: 20070270344Abstract: The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity.Type: ApplicationFiled: March 15, 2007Publication date: November 22, 2007Applicant: Fovea PharmaceuticalsInventor: Pierre Belichard